Research chemicalPsychedelicTryptamineSerotonergic
PT (N,N-Dipropyltryptamine variant / Propyltryptamine)
Also known as Propyltryptamine
PT refers to propyltryptamine-class research chemicals in the simple DMT-analog series. Extremely obscure with no formal human data; all information is anecdotal and structurally inferred.
01 Overview
PT is used informally for propyl-substituted tryptamines that occasionally appear on the research-chemical market alongside better-known homologs such as DPT. It has essentially no scientific literature of its own.
Given the total absence of pharmacokinetic or toxicological study, no reliable dosing or safety guidance can be provided. Figures here are indicative only and carry very high uncertainty.
02 Mechanism
Presumed 5-HT2A agonism shared by classical tryptamine psychedelics; not directly characterised.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common (reported) | 30–100 mg | Oral | Highly uncertain; anecdotal only. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Psychedelic effectsPresumed tryptamine-like perceptual and cognitive alteration; unverified. | unknown | Unconfirmed | |
| Altered moodMood changes reported anecdotally. | unknown | Unconfirmed |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Unknown toxicity profileNo toxicology data exists; harms cannot be excluded. | Moderate | Unknown | Unconfirmed | |
| Anxiety and disorientationDistressing psychological states possible, as with other psychedelics. | Moderate | Unknown | Unconfirmed |
06 Legal status
United Kingdom
Class A (tryptamine generic clause)
as of Jan 2026
United States
Possibly Analogue Act
as of Jan 2026
07 References
Shulgin A, Shulgin A. TIHKAL: The Continuation (tryptamine series)Transform Press, 1997
08 Discussion0 comments
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.